Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Study Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.

Conditions

Relapsed or Refractory B-cell Malignancies

Interventions / Drugs

EXS73565

View on ClinicalTrials.gov ↗

Sponsor

RXRX

Recursion Pharmaceuticals

AI Drug Discovery

D38/100

Study Details

Enrollment50 participants

Primary Completion—

Lead SponsorExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Data Retrieved2026-04-11 04:26:31.746401+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.